Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer


Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.

Dr. Boon joins Nyxoah from the Thomas Jefferson University, where he will continue part time as a professor and Vice Chairman, Education. He is dual board-certified in otolaryngology – head and neck surgery, as well as sleep medicine. Dr. Boon is one of two sleep surgeons with Jefferson Health to pioneer the use of hypoglossal nerve stimulation therapy (HGNS) and is internationally recognized as one of the most experienced surgeons performing HGNS procedures. He has lectured worldwide on obstructive sleep apnea, has numerous publications and is co-editor of the first book on HGNS.

“As an academic physician who has dedicated my professional career to the care of patients with sleep disordered breathing, I was privileged to participate in the DREAM U.S. pivotal trial. I was initially impressed by the results I saw in my patients and then equally impressed by the data that were recently reported. As such, I am honored to have been offered a position to join Nyxoah at such an exciting time. Bilateral hypoglossal nerve stimulation with Genio has tremendous potential and I am thrilled to work with their talented team to make a meaningful impact on the lives of patients with obstructive sleep apnea,” commented Dr. Boon.

“I could not be more excited to have Dr. Boon join Nyxoah. He is one of the pioneers in hypoglossal nerve stimulation and his decision to become Nyxoah’s Chief Medical Officer reflects Genio’s ability to improve the lives of OSA patients,” commented Olivier Taelman, Chief Executive Officer. “Dr. Boon will play a critical role as we prepare to enter the U.S. market and achieve our mission of making sleep simple again.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


Attachment

  • ENGLISH_Nyxoah Appoints Maurits Boon MD as Chief Medical Officer


Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

THỦ THUẬT HAY

Mách bạn bí quyết làm việc hiệu quả trên Outlook

Với việc cung cấp nhiều tính năng hấp dẫn, Outlook đã được nhiều người dùng lựa chọn so với những nền tảng email khác. Bài viết này sẽ cung cấp một số mẹo và thủ thuật hữu ích để bạn có thể sử dụng Outlook một cách

Hướng dẫn khắc phục các lỗi cơ bản trên iOS

Hệ điều hành iOS 10 đã được Apple cho ra mắt cách đây vài tháng, tuy đã trải qua khá nhiều bản cập nhật nhưng chắc chắn sẽ tồn tại nhiều lỗi và lỗ hổng nhỏ mà Apple chưa thể xử lý hết.

7 cách làm, tùy chỉnh trong bài sẽ giúp Windows 10 của bạn "nhanh như gió"

Bạn muốn tăng tốc Windows 10, cải thiện tốc độ Windows 10 hay tăng tốc khởi động Windows 10? Mọi cách tăng tốc Windows 10 đều có trong bài viết này, bạn hãy đọc và áp dụng để máy tính Windows 10 chạy nhanh hơn nhé!

8 thủ thuật Google Play có thể bạn chưa biết

Trong quá trình 'lượn lờ' trên Google Play bạn gặp những ứng dụng, game mình thích thì tốt nhất hãy lưu vào danh sách yêu thích để thuận tiện sử dụng mỗi khi cần thiết bằng cách: Nhấn vào biểu tượng Thêm vào danh sách

10 điều bạn phải nhớ trước khi muốn sửa chữa hay nâng cấp máy tính

Chắc chắn nhiều bạn đã từng nhiều lần sửa chữa hay nâng cấp máy tính của mình rồi, có thể gặp nhiều sai lầm dẫn đến kết quả là máy tính không thể hoạt động được. Vậy nên, hôm nay mình chia sẻ cho các bạn 10 điều phải

ĐÁNH GIÁ NHANH

Đánh giá realme narzo 30A: Thiết kế nổi bật, cấu hình tiện chiến game, đáng cân nhắc trong tầm giá 3-4 triệu

narzo 30A là chiếc smartphone vừa được realme cho ra mắt thị trường Việt Nam. Chiếc máy này không chỉ gây ấn tượng bởi cái tên có phần khác lạ so với dải sản phẩm vốn có của realme mà còn ấn tượng ở cả thiết kế mặt

Đánh giá Galaxy S7 chính hãng: Vẫn là lựa chọn đáng tiền hiện nay

Galaxy S7 chính hãng sở hữu ngôn ngữ thiết kế vừa quen vừa lạ. Quen ở đây là tương tự với các dòng điện thoại trước, nhưng được thêm một số điểm khác giúp hoàn thiện hơn – đó là lạ. Cụ thể ở mặt trước, mặt kính đi kèm

Đọ sức camera iPhone X, Galaxy Note8 và LG V30: "Kép dọc" có ngon hơn "kép ngang"?

Một bài test thực tế nhằm so sánh camera iPhone X và Galaxy Note 8 cùng LG V30 sẽ mang đến cho chúng ta một cái nhìn toàn diện về khả năng chụp ảnh trên ba siêu phẩm đình đám nhất hiện nay.